EMEA-000157-PIP01-07-M03

Key facts

Invented name
Nulojix
Active substance
belatacept
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0002/2017
PIP number
EMEA-000157-PIP01-07-M03
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Prevention of rejection of transplanted kidney
Route(s) of administration
Intravenous use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG

United Kingdom
Tel. +44 (0)1895 523740
Fax +44 (0)1895 523677
E-mail: medical.information@bms.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating